Rapport Therapeutics, Inc. entered a material agreement; reported results; took on a material financial obligation; sold unregistered shares
SEC 8-KRead source ↗
Rapport Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders7 buying, 6 selling11 purchases and 72 sales by directors and officers, last 12 monthsInsider trades
- Funds82 adding, 58 cuttingOf 34 active managers that changed their stake, 17 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Several insiders buying shares: 7 insiders bought shares in the open market in the past 90 days, according to their Form 4 filings.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Rapport Therapeutics, Inc.'s latest figures clears our strength thresholds.
Things to watch
- Volatile shares. Over the past year the shares showed annualised volatility of 62% and a beta of 1.1 against the S&P 500.
- Heavily shorted. 10.1% of the shares available to trade are sold short (6.7 days of average volume to cover).
- Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.
Latest results
- Earnings per share
- -$1.19 against an average estimate of -$0.99: missed by 20.4%
- Share reaction
- +3.8% in the first session after the results on October 30, 2026, against -2.2% for the S&P 500
- Next report
- November 5, 2026; average EPS estimate -$1.22
Price chart
- 1 day+0.3%
- 1 week-0.8%
- 1 month-21.9%
- This year-17.2%
- 1 year-13.1%
- S&P 500 this year+11.2%
Loading chart…
Third-party market data · may be delayed
At a glance
Earnings
- Last results
- October 30, 2026
- Next results (est.)
- January 28, 2027
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Results
- Insider trade
Healy James (Director) bought $20.4M of stock
SEC Form 4 - Announcement
Rapport Therapeutics, Inc. made a public disclosure; disclosed a material event
SEC 8-KRead source ↗ - Results
Rapport Therapeutics, Inc. reported results
SEC 8-KRead source ↗
No model value for Rapport Therapeutics, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.
Valuation models
We value Rapport Therapeutics, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.1%: the 10-year Treasury yield (4.9%) plus a beta of 1.14 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | — | No model applies: the filings don’t yet support a value. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Rapport Therapeutics, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Next results: November 5, 2026, before the open. Analysts expect revenue of $0 and EPS of −$1.22 (range −$1.36 to −$1.08) for the quarter.
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$4.04 | −41% | $20m | 0% |
| Next | −$5.09 | −26% | — | −100% |
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is +18.6% on 90 days ago. In the last 30 days, 1 analyst raised Rapport Therapeutics, Inc.'s forecast and 0 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$3.40 | −$4.27 |
| 60 days ago | −$4.09 | −$5.23 |
| 30 days ago | −$4.09 | −$5.23 |
| 7 days ago | −$4.04 | −$5.11 |
| Now | −$4.04 | −$5.09 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.99 | −$1.19 | −20.4% |
| Mar 2026 | −$0.71 | −$0.42 | +40.7% |
| Dec 2025 | −$0.67 | −$0.72 | −6.8% |
| Sept 2025 | −$0.73 | −$0.71 | +3.0% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 10.1% of tradable shares
- Days to cover
- 6.7 at average volume
- Short interest, 1 month
- +36% to October 15, 2026
- Held by institutions
- 97% of shares
- Held by insiders
- 3.3% of shares
- Employees
- 84 full time
Share-price performance
Market data may be delayedReturn and risk by year
| Calendar year | 2025 | 2026 to date |
|---|---|---|
| Return | ||
| RAPP | +71% | −17% |
| Industry peers (median) | −5% | −27% |
| S&P 500 | +18% | +11% |
| Months that ended higher | ||
| RAPP | 58% | 64% |
| S&P 500 | 75% | 46% |
| Largest fall from a high during the year | ||
| RAPP | −63% | −57% |
| S&P 500 | −19% | −9% |
Worst fall since June 7, 2024: 76% from October 16, 2024 to March 3, 2025. Getting back needed a 309% gain, reached on September 8, 2025, 189 days after the low.
Price behaviour
- 52-week range
- $22.50 – $52.50
- From 52-week high
- −52.1%
- vs 50-day average
- −30.7%
- vs 200-day average
- −29.5%
- Volatility (1 year)
- 62%
- Beta vs S&P 500
- 1.06
Share price after results
- Next day
- 7 up, 3 down typical move ±4.3%
- After a week
- 5 up, 4 down typical move ±9.0%
- After a month
- 7 up, 2 down typical move ±23.9%
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| October 30, 2026 | +3.8% | −2.2% | — | — |
| August 5, 2026 | +9.8% | −0.4% | +13.1% | +12.9% |
| May 7, 2026 | +2.6% | +0.5% | +2.4% | −1.0% |
| March 10, 2026 | 0.0% | −0.3% | −9.2% | +12.0% |
| November 6, 2025 | −1.9% | −1.0% | −5.7% | +15.2% |
| August 7, 2025 | −0.4% | +0.7% | +2.3% | +115.4% |
| May 8, 2025 | +0.3% | +0.6% | −4.5% | +24.4% |
| March 11, 2025 | +21.0% | −0.3% | +20.1% | +8.6% |
| November 7, 2024 | +2.1% | +1.2% | −15.9% | −21.5% |
| August 8, 2024 | +1.1% | +2.8% | +8.1% | +4.2% |
Fundamentals
Who owns it
Funds buying and selling- Reported value
- $2.1B
- Institutions reporting
- 160
- Shares held vs prior quarter
- ▼ 2.3%
- Positions opened / closed
- 26 / 12
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| FMR LLC | $299M | 7.2M | 14.0% | ▲ 0.1% |
| Trv Gp V, LLC | $262M | 6.3M | 12.3% | ▼ 12.0% |
| Arch Venture Management, LLC | $155M | 3.7M | 7.3% | 0.0% |
| Capital International Investors | $122M | 2.9M | 5.7% | ▼ 5.7% |
| Goldman Sachs Group Inc | $121M | 2.9M | 5.7% | ▼ 1.1% |
| Blackrock, Inc. | $113M | 2.7M | 5.3% | ▲ 7.7% |
| Cormorant Asset Management, LP | $111M | 2.7M | 5.2% | ▼ 10.1% |
| Sofinnova Investments, Inc. | $79.4M | 1.9M | 3.7% | 0.0% |
| Johnson & Johnson | $74.4M | 1.8M | 3.5% | 0.0% |
| Polar Capital Holdings PLC | $67M | 1.6M | 3.1% | ▼ 2.1% |
| Baker Bros. Advisors LP | $64.5M | 1.5M | 3.0% | 0.0% |
| Vanguard Capital Management LLC | $56.1M | 1.3M | 2.6% | ▲ 1.6% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Rapport Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chart Insider purchases History → $22M 11 trades by 7 insiders, last 12 months Insider sales History → $47.2M 72 trades by 6 insiders · 99% under pre-set plans
Net ▼ $25.2M net selling
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Healy James Director | October 28, 2026 | Buy | 6,933 | $21.00 | $145,593 |
| Healy James Director | October 28, 2026 | Buy | 3,772 | $21.00 | $79,212 |
| Healy James Director | October 28, 2026 | Buy | 6,395 | $21.00 | $134,295 |
| Healy James Director | October 28, 2026 | Buy | 952,380 | $21.00 | $20M |
| Sanchez Ramiro Director | October 23, 2026 | Buy | 3,600 | $27.35 | $98,478 |
| Maraganore John Director | October 22, 2026 | Buy | 1,172 | $26.92 | $31,547 |
| Maraganore John Director | October 22, 2026 | Buy | 8,239 | $26.38 | $217,344 |
| Paul Steven M Director | October 22, 2026 | Buy | 35,714 | $27.28 | $974,278 |
| Young Wendy B. Director | October 22, 2026 | Buy | 3,789 | $26.39 | $99,992 |
| Silva Paul M Director | October 22, 2026 | Buy | 3,680 | $27.07 | $99,636 |
| Ignelzi Troy A. Chief Financial Officer | October 21, 2026 | Buy | 5,500 | $26.10 | $143,550 |
| Ceesay Abraham Chief Executive Officer | October 21, 2026 | Sell pre-set plan | 2,210 | $29.16 | $64,448 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
Next expected around January 28, 2027 estimated from the company's past filing pattern, not announced
- October 30, 2026
- August 5, 2026
- May 7, 2026
- March 10, 2026
- November 6, 2025
- August 7, 2025
Recent SEC filings
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- DEF 14A Proxy statement
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Rapport Therapeutics, Inc. in brief
- What does Rapport Therapeutics, Inc. do?
- Rapport Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Rapport Therapeutics, Inc.'s stock ticker?
- Rapport Therapeutics, Inc. trades under the ticker RAPP on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Rapport Therapeutics, Inc.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are FMR LLC, Trv Gp V, LLC and Arch Venture Management, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- Are insiders buying or selling Rapport Therapeutics, Inc. stock?
- Over the last 12 months, Rapport Therapeutics, Inc.'s directors and officers reported 11 open-market purchases and 72 sales on Form 4. The insider trading page charts every trade.
- When is Rapport Therapeutics, Inc.'s next earnings date?
- Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Rapport Therapeutics, Inc. announces its own schedule.
Follow research on Rapport Therapeutics, Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.